ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
// Qiongrong Chen 1, 3 , Shumei Song 1 , Shaozhong Wei 3 , Bin Liu 4 , Soichiro Honjo 1 , Ailing Scott 1 , Jiankang Jin 1 , Lang Ma 1 , Haitao Zhu 1 , Heath D. Skinner 2 , Randy L. Johnson 2 , Jaffer A. Ajani 1 1 Departments of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA 2 Departments of Biochemistry & Molecular Biology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA 3 Hubei Cancer Hospital, Wuhan 430079, China 4 Departments of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA Correspondence to: Shumei Song, e-mail: ssong@mdanderson.org Jaffer A. Ajani, e-mail: jajani@mdanderson.org Keywords: esophageal cancer, stemness pathways, cancer stem cells, ABT-263, 5-fluorouracil Received: March 12, 2015 Accepted: July 06, 2015 Published: July 17, 2015 ABSTRACT Activation of cancer stem cell signaling is central to acquired resistance to therapy in esophageal cancer (EC). ABT-263, a potent Bcl-2 family inhibitor, is active against many tumor types. However, effect of ABT-263 on EC cells and their resistant counterparts are unknown. Here we report that ABT-263 inhibited cell proliferation and induced apoptosis in human EC cells and their chemo-resistant counterparts. The combination of ABT-263 with 5-FU had synergistic lethal effects and amplified apoptosis that does not depend fully on its inhibition of BCL-2 family proteins in EC cells. To further explore the novel mechanisms of ABT-263, proteomic array (RPPAs) were performed and gene set enriched analysis demonstrated that ABT-263 suppresses the expression of many oncogenes including genes that govern stemness pathways. Immunoblotting and immunofluorescence further confirmed reduction in protein expression and transcription in Wnt/β-catenin and YAP/SOX9 axes. Furthermore, ABT263 strongly suppresses cancer stem cell properties in EC cells and the combination of ABT-263 and 5-FU significantly reduced tumor growth in vivo and suppresses the expression of stemness genes. Thus, our findings demonstrated a novel mechanism of ABT-263 antitumor effect in EC and indicating that combination of ABT-263 with cytotoxic drugs is worthy of pursuit in patients with EC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603 · cited 2×
“Nevertheless, in some xenograft models of aggressive lymphoma and in phase I/II clinic studies in patients of lung cancer, singleagent of ABT-263 just exhibited modest or limited efficacy [10, 11, 15] with dose-dependent thrombocytopenia”
Background
Research works printed but not linked: 41
- Jemal, 2014, Cancer statistics, 2014, CA: a cancer journal for clinicians, 64, 9
- Bonenkamp, 2012, Preoperative chemoradiotherapy for esophageal or junctional cancer, The New England journal of medicine, 366, 2074, 10.1056/NEJMoa1112088 · DOI · Paper page
- Hayman, 2011, Esophageal and esophagogastric junction cancers, Journal of the National Comprehensive Cancer Network : JNCCN, 9, 830, 10.6004/jnccn.2011.0072 · DOI · Paper page
- Ajani, 2012, Failure patterns in patients with esophageal cancer treated with definitive chemoradiation, Cancer, 118, 2632, 10.1002/cncr.26586 · doi:10.1002/cncr.26586
- Grant, 2011, Targeting Mcl-1 for the therapy of cancer, Expert opinion on investigational drugs, 20, 1397, 10.1517/13543784.2011.609167 · DOI · Paper page
- Strasser, 2011, The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy, Cell death and differentiation, 18, 1414, 10.1038/cdd.2011.17 · DOI · Paper page
- Reynolds, 2009, Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy, Clinical cancer research : an official journal of the American Association for Cancer Research, 15, 1126, 10.1158/1078-0432.CCR-08-0144 · DOI · Paper page
- Dlamini, 2005, The molecular mechanisms of oesophageal cancer, International immunopharmacology, 5, 1113, 10.1016/j.intimp.2004.11.017 · DOI
- Caligiuri, 2013, Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target, Leukemia, 27, 1996, 10.1038/leu.2013.151 · DOI
- Fairlie, 2012, Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells, Blood, 119, 5807, 10.1182/blood-2011-12-400929 · DOI · Paper page
- Liu, 2011, Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells, PloS one, 6, e21980, 10.1371/journal.pone.0021980 · DOI
- Leverson, 2012, Navitoclax (ABT-263) and bendamustine +/− rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours, British journal of pharmacology, 167, 881, 10.1111/j.1476-5381.2012.02048.x · DOI · Paper page
- Ramalingam, 2012, Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer, Clinical cancer research : an official journal of the American Association for Cancer Research, 18, 3163, 10.1158/1078-0432.CCR-11-3090 · DOI · Paper page
- Bauch, 2008, ABT-263 and rapamycin act cooperatively to kill lymphoma cellsand, Molecular cancer therapeutics, 7, 3265, 10.1158/1535-7163.MCT-08-0268 · DOI · Paper page
- Chekenya, 2007, Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies, Neoplasia, 9, 882, 10.1593/neo.07658 · DOI · Paper page
- Petrovic, 2013, Reciprocal regulation by TLR4 and TGF-beta in tumor-initiating stem-like cells, The Journal of clinical investigation, 123, 2832, 10.1172/JCI65859 · DOI · Paper page
- Weston, 2014, Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties, Cancer research, 74, 4170, 10.1158/0008-5472.CAN-13-3569 · DOI · Paper page
- Magne, 2012, Targeting a cornerstone of radiation resistance: cancer stem cell, Cancer letters, 322, 139, 10.1016/j.canlet.2012.03.024 · DOI
- Albarracin, 2015, The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer, Clinical cancer research : an official journal of the American Association for Cancer Research, 21, 2580, 10.1158/1078-0432.CCR-14-2191 · DOI · Paper page
- Chao, 2007, Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport, Oncogene, 26, 5674, 10.1038/sj.onc.1210356 · DOI · Paper page
- Ajani, 2006, Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response, Clinical cancer research : an official journal of the American Association for Cancer Research, 12, 6565, 10.1158/1078-0432.CCR-06-0176 · DOI · Paper page
- Wang, 2012, The crosstalk of mTOR/S6K1 and Hedgehog pathways, Cancer cell, 21, 374, 10.1016/j.ccr.2011.12.028 · DOI · Paper page
- Yu, 2011, Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis, Clinical cancer research : an official journal of the American Association for Cancer Research, 17, 2130, 10.1158/1078-0432.CCR-10-2467 · DOI · Paper page
- Haber, 2006, Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon, Proceedings of the National Academy of Sciences of the United States of America, 103, 12405, 10.1073/pnas.0605579103 · DOI · Paper page
- Weston, 2014, Hippo coactivator YAP1 upregulates SOX9 and endows stem-like properties to esophageal cancer cells, Cancer Res, 74, 4170, 10.1158/0008-5472.CAN-13-3569 · DOI · Paper page
- Peters, 1988, Fluorouracil: biochemistry and pharmacology, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 6, 1653, 10.1200/JCO.1988.6.10.1653 · DOI · Paper page
- Hiyoshi, 2010, Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells, BMC cancer, 10, 370, 10.1186/1471-2407-10-370 · DOI · Paper page
- Milas, 2006, Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 80, 185, 10.1016/j.radonc.2006.07.027 · doi:10.1016/j.radonc.2006.07.027
- Brody, 2008, Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil, Is it time to move forward? Cancer biology & therapy, 7, 986
- Shirata, 2012, Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study, BMC cancer, 12, 542, 10.1186/1471-2407-12-542 · DOI
- Roberg, 2014, YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer, Oral oncology, 50, 832, 10.1016/j.oraloncology.2014.06.003 · DOI
- Chen, 2013, Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma, Oncology reports, 29, 840, 10.3892/or.2012.2176 · DOI
- Bresalier, 2009, Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity, Cancer research, 69, 1343, 10.1158/0008-5472.CAN-08-4153 · DOI · Paper page
- Guan, 2009, Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein, Cancer research, 69, 1089, 10.1158/0008-5472.CAN-08-2997 · DOI · Paper page
- Stroehlein, 2013, Loss of TGF-beta adaptor beta2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma, Cancer research, 73, 2159, 10.1158/0008-5472.CAN-12-1962 · DOI
- Maru, 2014, ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients, Molecular oncology, 8, 142, 10.1016/j.molonc.2013.10.007 · DOI
- Reynolds, 2003, Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation, Dis Esophagus, 16, 17, 10.1046/j.1442-2050.2003.00281.x · DOI
- Bi, 2014, SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma, Oncogene, 33, 1468, 10.1038/onc.2013.88 · DOI
- Ajani, 2015, The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer, Clin Cancer Res, 21, 2580, 10.1158/1078-0432.CCR-14-2191 · DOI · Paper page
- Bresalier, 2009, Polyphenon E inhibits the growth of human Barrett's and aerodigestive adenocarcinoma cells by suppressing cyclin D1 expression, Clinical cancer research : an official journal of the American Association for Cancer Research, 15, 622, 10.1158/1078-0432.CCR-08-0772 · DOI
- Meric-Bernstam, 2010, A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers, Clinical proteomics, 6, 129, 10.1007/s12014-010-9055-y · DOI · Paper page
Cited by
Cardiac glycosides are broad-spectrum senolytics
Guerrero, A., Herranz, N., Sun, B., Wagner, V., Gallage, S., Guiho, R., Wolter, K., Pombo, J., Irvine, E. E., Innes, A. J., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0122-z · Cited by 359
Advances and challenges in the treatment of esophageal cancer
He, S., Xu, J., Liu, X., & Zhen, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.008 · Cited by 287
Galactose‐modified duocarmycin prodrugs as senolytics
Guerrero, A., Guiho, R., Herranz, N., Uren, A., Withers, D. J., Martínez‐Barbera, J. P., Tietze, L. F., & Gil, J. (2020) · Aging Cell · doi:10.1111/acel.13133 · Cited by 172
Metadata
- Authors
- Chen, Q., Song, S., Wei, S., Liu, B., Honjo, S., Scott, A., Jin, J., Ma, L., Zhu, H., Skinner, H. D., Johnson, R. L., & Ajani, J. A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-07-17
- Volume
- 6
- Issue
- 28
- Pages
- 25883-25896
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2104234534
- Cited by
- 42
- References
- 4
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. https://app.cochat.ai/papers/10.18632/oncotarget.4540
- The paper
- Chen, Q., Song, S., Wei, S., Liu, B., Honjo, S., Scott, A., Jin, J., Ma, L., Zhu, H., Skinner, H. D., Johnson, R. L., & Ajani, J. A. (2015). ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget. https://doi.org/10.18632/oncotarget.4540
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.